RxDoctor Payments Data

Abdelle Ferdinand Cheres, MD

Endocrinology, Diabetes & Metabolism · Streetsboro, OHNPI 1881949865

Payments from drug & device makers

$585in general payments, 2019–2025

Across 38 payments — averaging $15.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Dexcom, Inc.$156
  • Novo Nordisk$145
  • Medtronic$65
  • AbbVie$59
  • Xeris Pharmaceuticals, Inc.$50
  • Tandem Diabetes Care, Inc.$29
  • plus $80 from 5 others

What the payments were for

  • Food & beverage$47681%
  • Education$10919%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$585 in reported general payments places this provider in the 30th percentile of 312 endocrinology, diabetes & metabolism providers in Ohio.

See all endocrinology, diabetes & metabolism providers in Ohio

Medicare billing

Part B allowed, 2024
$76,503
Medicare patients
316
Services billed
986

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide372$397,006
JardianceEmpagliflozin412$381,564
TrulicityDulaglutide224$251,409
FarxigaDapagliflozin Propanediol246$207,849
MounjaroTirzepatide138$155,673
Humulin R U-500 KwikpenInsulin Regular, Human98$151,527
JanuviaSitagliptin Phosphate132$123,879
Lantus SolostarInsulin Glargine,hum.Rec.Anlog451$75,027
Omnipod Dash Pods (Gen 4)Insulin Pump Cart,cont Inf,bt54$64,725
Humalog Kwikpen U-100Insulin Lispro223$63,877
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/750$62,808
RybelsusSemaglutide59$60,519
JanumetSitagliptin Phos/Metformin Hcl41$48,607
Tresiba Flextouch U-100Insulin Degludec75$48,549
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog113$47,383

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus, Fiasp$145$470,263444 claims
Lilly USA, LLCTrulicity, Mounjaro, Humalog, Insulin Lispro$14$430,977480 claims
Boehringer IngelheimJardiance, Tradjenta$11$409,666446 claims
AbbVieSynthroid$59$7,164156 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 312 endocrinology, diabetes & metabolism providers in Ohio.

Other endocrinology, diabetes & metabolism in Streetsboro

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →